Background The first national recommendations on neuraxial anaesthesia and
antithrombotic drugs were published by the German Society for Anaesthesiology and …

Phosphodiesterases (PDEs) are a superfamily of enzymes that hydrolyze cyclic nucleotides,
including cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate …

Background: Interventional pain management is a specialty that utilizes invasive procedures
to diagnose and treat chronic pain. Patients undergoing these treatments may be receiving …

Background Cilostazol overcomes high on-treatment platelet reactivity (HTPR) and reduces
adverse cardiovascular (CV) outcomes after percutaneous coronary intervention (PCI) …

Introduction: Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly
improve walking distance in patients with intermittent claudication. However, beyond its …

Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with
a low rate of bleeding complications. It has been used over the past 25 years for improving …

Objective Cilostazol is an antiplatelet agent with vasodilatory effects that works by increasing
intracellular concentrations of cyclic adenosine monophosphate (cAMP). This study …

The aim of this study was to obtain best estimates of the efficacy and safety of cilostazol-
based triple antiplatelet therapy (TAPT: aspirin, clopidogrel and cilostazol) compared with …

288 PARK KW et al. patients had significantly higher clopidogrel OPR than noncarriers. 31 If
we consider the CYP2C19* 3 LOF allele, which is almost non-existent in Caucasian …

Cilostazol is a generic drug with antiplatelet and antiproliferative effects. It is unclear whether
adding cilostazol to standard dual antiplatelet therapy (aspirin and clopidogrel) after …